LGVN Stock Summary and Trading Ideas (Longeveron - Class A | NASDAQ:LGVN)

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Longeveron - Class A trades on the NASDAQ stock market under the symbol LGVN.

As of December 26, 2025, LGVN stock price was flat at $0.53 with 156,194 million shares trading.

LGVN has a beta of 0.78, meaning it tends to be less sensitive to market movements. LGVN has a correlation of 0.02 to the broad based SPY ETF.

LGVN has a market cap of $11.36 million. This is considered a Sub-Micro Cap stock.

Last quarter Longeveron - Class A reported $137,000 in Revenue and -$.39 earnings per share. This fell short of revenue expectation by $-145,802 and missed earnings estimates by -$.14.

In the last 3 years, LGVN traded as high as $45.79 and as low as $.52.

The top ETF exchange traded funds that LGVN belongs to (by Net Assets): VTI, VXF.

LGVN has underperformed the market in the last year with a price return of -71.1% while the SPY ETF gained +16.0%. LGVN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -33.3% and -12.5%, respectively, while the SPY returned +4.6% and +1.5%, respectively.

LGVN support price is $.50 and resistance is $.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LGVN shares will trade within this expected range on the day.